Life Sciences

We recognise that innovation needs execution in order to realise value. We also understand that life sciences are long term investments and usually require a number of funding rounds before reaching cash breakeven or being sold.  Confidentiality prohibits us from publishing specific examples of our work in this area which include:

  • Building financial models with sufficient clarity to support funding applications;
  • Designing charts of accounts to ensure efficient R&D tax credit claims; and
  • Building accounting and management information systems to provide high quality information to ensure that variances from targets are clearly and quickly identified so that corrective action can be taken before it’s too late.

Our team of commercially experienced finance directors has been helping Life Science companies over the last 20 years to build robust integrated forecast models to support funding applications, design charts of accounts to ensure efficient R&D tax credit claims and build accounting and management information systems to provide high quality information to help management make the right decisions.

 

“Amazing – honest, transparent, smart, hard-working and you genuinely care about my business. I am grateful for your professionalism.”
Alex Alverez, Director, RioBlush UK Limited


Our team

Kim Dovell

Kim Dovell

Kim Dovell spent 20 years with BTG plc, where she managed a large US/UK team and was part of the executive committee and played major roles in fundraising transactions totaling £250 million. Kim provided FD and company secretarial support to a private equity-backed company focussed on development of clinically-relevant medicines for multiple sclerosis and related orphan disorders.

Robert McLaurin

Robert McLaurin

Robert McLaurin has supported two life sciences start-ups by developing robust financial models to assist them in their search for initial funding from investors – the first , a synthetic biology start-up, raised £700,000 from angel investors, and the second, a start-up developing an early detection device for colorectal cancer, raised £300,000. Robert provides ongoing advice and support to both companies.

Chris Backhouse

Chris Backhouse

Chris Backhouse led the restructuring and profit-improvement plan of Swiss-owned Unilabs Group, reorganising laboratory operations, reducing headcount by 35% and eliminating losses within 18 months. He refinanced the business by way of a sale-and-leaseback of its London premises and prepared the group for merger with a smaller rival.

Jim Halliday

Jim Halliday

Jim Halliday obtained £800,000 in Research & Development tax credits for a biotech focussed on bone disease.